Medicamen Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the stock exchanges. The filing, dated September 3, 2026, discloses key operational and financial metrics for the period ending March 31, 2026.

The company reported a total turnover of ₹1,788.46 crore and a profit after tax of ₹94.09 crore. The report also details the company’s sustainability initiatives, governance structures, and compliance with the National Guidelines on Responsible Business Conduct (NGRBC).

Financial Overview

The BRSR filing provides a snapshot of the company’s financial performance for FY26. Alongside the revenue figure, the report discloses the paid-up capital and corporate social responsibility (CSR) spending.

Regarding CSR obligations under Section 135 of the Companies Act, 2013, the company was required to spend ₹31.33 lakh. It incurred ₹25.20 lakh during the year on education and health projects. An unspent amount of ₹6.13 lakh, not related to any ongoing project, is to be transferred to the fund specified in Schedule VII of the Act.

Operational Highlights

Medicamen Biotech operates three manufacturing facilities in India: one in Bhiwadi, Rajasthan, and two units in Haridwar, Uttarakhand. The company serves markets across more than 35 countries, with approximately 80% of its sales generated from international markets. Its product portfolio includes formulations for Oncology, Cardiovascular, Diabetic, and Hypertension treatments, as well as Nutraceuticals.

The company has two subsidiaries: OPAL Pharmaceuticals Pty Ltd in Australia (wholly owned) and Medicamen Life Sciences Private Limited (60% stake). Shivalik Rasayan Limited holds a 40.46% stake in Medicamen Biotech as its holding company.

Governance and Compliance

The report identifies Rahul Bishnoi, Chairman, as the director responsible for implementing business responsibility policies. The Board of Directors, supported by the Stakeholders' Relationship Committee, oversees sustainability strategy and ESG initiatives.

During FY26, the company paid a penalty of ₹7,080 to the National Stock Exchange of India Limited for non-compliance with Regulation 31 of the SEBI Listing Regulations regarding the delay in filing the Shareholding Pattern. No other fines, penalties, or disciplinary actions related to bribery or corruption were reported.

What the Numbers Show

The data reveals a significant concentration in export revenue, with international markets contributing roughly four-fifths of the total turnover. This heavy reliance on overseas sales suggests that the company’s financial performance is closely tied to global regulatory approvals and currency dynamics across its 35+ served countries. Additionally, the rise in related-party purchases to 11.86% from 5.57% in the previous year indicates a growing dependency on specific supply chain partners.

Medicamen Biotech has fixed September 19, 2026, as the record date for the payment of the final dividend for the financial year ended March 31, 2026 (FY26). Shareholders whose names appear in the Register of Members or depository records as on this date will be eligible to receive the dividend, subject to its declaration at the ensuing Annual General Meeting.

The Board of Directors has recommended the final dividend, which requires approval from members at the company’s 33rd Annual General Meeting. The intimation was issued in compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 91 of the Companies Act, 2013.

Book Closure Details

To facilitate the AGM and dividend payment process, Medicamen Biotech will close its Register of Members and Share Transfer Books for a period of seven days. The closure applies to equity shares listed on both the BSE and NSE.

The book closure period runs from Sunday, September 20, 2026, to Saturday, September 26, 2026, inclusive of both days. During this period, no transfers or transmissions of shares will be processed.

Regulatory Compliance

The disclosure was submitted to the stock exchanges by Parul Choudhary, Company Secretary, on August 18, 2026. The company emphasized that the dividend entitlement is strictly determined by the record date and is subject to applicable laws and shareholder approval at the AGM.